London Calling for Tesla (TSLA) as Self-Driving Passes Magic Test
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Roundabout Regulations
The company released two videos today showing the successful testing of its fully self-driving vehicles in the traditionally warren-like and congested roads of Great Britain. It helped its share price climb nearly 4%.
The videos showed the group's Model 3 car navigating busy London streets and passing landmarks such as Big Ben and Buckingham Palace. It also showed the vehicle coping with the so-called Magic Roundabout in Swindon, in the West of England. Americans might know these as traffic circles.
The Magic Roundabout consists of five mini roundabouts encircling a central island, and was voted U.K. roundabout of the year in 2024. It has a number of descriptions ranging from 'amazing' to a 'white knuckle ride.'
Tesla said the Model 3 used for the videos contains the same hardware as vehicles delivered to customers today, but has software currently available only to its engineers.
Tesla Troubles
The company is still awaiting regulatory approval to use its unsupervised full self-driving capabilities in the U.K., but this is a step in the right direction.
Steve Gooding, director of motoring research charity the RAC Foundation was certainly impressed. He said: 'It is a mistake to think that driverless technology won't be able to cope with the intricacies and idiosyncrasies of the U.K.'s roads – hats off to anyone, or anything, that can successfully negotiate the Magic Roundabout.'
However, he cautioned that more testing was needed.
Tesla has itself been in a spin this week, following disappointing results, and this year as a combination of more intense competition and chief executive Elon Musk's on and very much off relationship with President Trump battered brand reputation and investor sentiment.
Tesla also faces the loss of the $7,500 EV tax credit and stands to make much less money from selling regulatory credits to other automakers after recent changes to federal tax law.
It really needs its self-driving venture to prove its mettle in London, Swindon and beyond.
Is TSLA a Good Stock to Buy Now?
On TipRanks, TSLA has a Hold consensus based on 14 Buy, 14 Hold and 7 Sell ratings. Its highest price target is $500. TSLA stock's consensus price target is $314.48, implying a 0.71% downside.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
31 minutes ago
- Business Insider
This Is How Apple (AAPL) Is Staying on Trump's Good Side
President Trump has openly said that he wants tech giant Apple (AAPL) to build iPhones in the U.S., but CEO Tim Cook is taking a different path. Instead of agreeing to move final iPhone assembly to the U.S., Cook joined Trump at the White House to announce a $600 billion investment over four years. This doesn't include making iPhones entirely in the U.S., but it highlights Apple's work with American companies that already make important parts like the glass and facial recognition sensors. Still, Cook explained that final assembly will continue to happen elsewhere. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. It is worth noting that the new 'American Manufacturing Program' looks to help U.S. suppliers grow by strengthening Apple's partnerships with them. For example, all cover glass for iPhones and Apple Watches will be made by Corning (GLW) in Kentucky, with Apple investing $2.5 billion in the effort. Apple also extended its deals with Texas-based companies like Coherent (COHR) and Texas Instruments (TXN), and said that it will be buying advanced chips from TSMC's (TSM) Arizona factory, where Apple will be the main customer. In addition, Apple is expanding its U.S. data centers in North Carolina, Iowa, Nevada, and Oregon in order to support artificial intelligence. Although the announcement pleased Trump and boosted Apple's stock, analysts are unsure how much it will really impact Apple's profits. Indeed, Apple hasn't shared exact spending details, and most supplier agreements are confidential. Interestingly, experts believe that the $600 billion figure likely includes regular costs like payroll, Apple TV+ productions, and ongoing supplier payments. As a result, some see this move as a smart way for Apple to stay on Trump's good side and avoid tariffs, without making big changes to its business model. Is Apple a Buy or Sell Right Now? Turning to Wall Street, analysts have a Moderate Buy consensus rating on AAPL stock based on 15 Buys, 12 Holds, and one Sell assigned in the past three months, as indicated by the graphic below. Furthermore, the average AAPL price target of $234.93 per share implies 4.1% upside potential.
Business Insider
31 minutes ago
- Business Insider
Nintendo Stock (NTDOF) Stock Jumps on Gamescom 2025 Booth Lineup
Nintendo (NTDOF) stock was up on Friday after the video game company revealed its lineup for Gamescom 2025. The game hardware and software developer will host a mix of first- and third-party games at its Gamescom booth. On the first-party front, attendees will be able to experience Pokemon Legends: Z-A, Metroid Prime 4: Beyond, and a collection of Nintendo GameCube Classics. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Looking at third-party games, Nintendo has chosen some interesting titles to show off on the Switch 2. That includes the long-awaited Hollow Knight: Silksong, Square Enix's (SQNXF) Final Fantasy 7 Remake Intergrade, CD Projekt's (OTGLY) Cyberpunk 2077: Ultimate Edition, Kadokawa (JP:9468) subsidiary FromSoftware's Elden Ring, and several others. Gamescom 2025 will start on August 20 and last through August 24. Attendees can also use their Nintendo Account at the company's booth to redeem 100 Platinum Points on My Nintendo and an exclusive pin. Nintendo Stock Movement Today Nintendo stock was up 3.07% on Friday, extending a 66.38% rally year-to-date. The shares have also increased 79.87% over the past 12 months. The success of the Switch 2, released in early June, has strongly contributed to these stock gains. Nintendo also recently . This was in response to President Donald Trump's increased tariffs. This hasn't affected the price of the Switch 2 yet, but ongoing trade war actions could cause problems for NTDOF stock. Is Nintendo Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Nintendo is Moderate Buy, based on nine Buy, two Hold, and a single Sell rating over the past three months. With that comes an average NTDOF stock price target of $98.61, representing a potential 1.78% upside for the shares.
Business Insider
an hour ago
- Business Insider
Pfizer's (PFE) Turnaround Story Fades as Headwinds Approach
Pfizer's (PFE) Q2 earnings show the company is finally moving past the tough comparisons created by its pandemic-era boom. Pfizer reported superb Q2 figures, with significant year-over-year growth in revenue and EPS while also reaffirming its revenue guidance for the year. The positive earnings news pushed the stock up to as high as $25 per share, only briefly, before the bears regained control. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. At the height of COVID-19, the pharma giant enjoyed a massive surge in vaccine and treatment revenue. But as the pandemic faded and routine COVID immunizations declined, year-over-year revenue took a sharp hit. Now, with that chapter largely behind it, Pfizer's top line is regaining momentum, fueled by innovative blockbusters like VYNDAQEL and ELIQUIS. Still, the road ahead isn't without hazards. Loss of patent exclusivity (LoE) on key drugs and looming regulatory shifts could weigh on future performance. With risk and opportunity so closely intertwined, I'm maintaining a Neutral stance on PFE—despite its latest earnings blowout. —a remarkable feat for a company of its size, where each percentage point becomes harder to achieve. But revenue growth only matters if profits keep pace. On that front, Pfizer delivered as well, aided by cost discipline: research & development spending fell 9%, while selling, general, and administrative expenses dropped 8%. The result? Adjusted diluted EPS came in at $0.78, beating expectations by nearly $0.20. That may not sound earth-shattering—until you remember Pfizer has more than 5.6 billion shares outstanding. That kind of beat adds up fast. Growth Drivers: Vyndaqel, Eliquis, and Oncology Lead the Way Pfizer's strong performance is being powered by standout drugs. The VYNDAQEL family—its treatment for transthyretin-mediated amyloidosis cardiomyopathy— jumped 21% year-over-year to $1.615 billion, making it Pfizer's second-largest revenue source. Its top seller, the blood thinner ELIQUIS, grew 6% to over $2 billion in Q2, fueled by rising global demand in the expanding anticoagulant market. While blockbuster IBRANCE is slipping post–loss of exclusivity, Pfizer's Oncology division remains a powerhouse, generating $4.387 billion in Q2—an 11% increase from last year. Navigating the Storm: Patent Cliffs and Pricing Pressures That said, Pfizer has several pressing challenges on the horizon. Multiple key products—including ELIQUIS—face looming patent expirations over the next few years, putting an estimated $17 billion in annual revenue at risk. To put that in perspective, that's more than an entire quarter's worth of sales. The Inflation Reduction Act (IRA) Medicare Part D Redesign is also weighing on U.S. revenue. In fact, without the 'higher impact discounts' tied to the IRA changes, ELIQUIS's Q2 growth would have been even stronger. Adding to the pressure, Pfizer must navigate geopolitical headwinds—such as tariffs—and potential pricing impacts from Most-Favored-Nation policies. Future Growth: Pipeline Catalysts and Strategic Acquisitions Pfizer isn't standing still—it's been navigating the drug lifecycle for decades. With more than 80 programs in its R&D pipeline, including 23 in Phase 3 trials, the company is positioning itself for the next wave of growth. Oncology remains a core focus, bolstered by the $43 billion acquisition of Seagen in 2023, which is projected to generate roughly $20 billion in risk-adjusted revenue by 2030. One closely watched candidate is SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently in development for non-small cell lung cancer (NSCLC) and other indications. While the PD-1/VEGF class is crowded, it carries ambitions of challenging Merck's (MRK) KEYTRUDA in an NSCLC market expected to surpass $40 billion by 2030. PFE Could be a Discounted Opportunity Without a valuation context, the rest is just noise. Pfizer's P/E ratio of 12.5 sits roughly 49% below the Health Care sector average. Yet the stock has lagged badly, delivering -32% returns over the past decade. Its hefty 6.91% dividend yield may look appealing, but investors should weigh it against the company's long history of underperformance. Is PFE a Buy, Sell, or Hold? On Wall Street, Pfizer carries a Moderate Buy consensus rating based on five Buy, 12 Hold, and zero Sell ratings in the past three months. PFE's average price target of $28.73 implies ~18% upside potential over the next twelve months. Earlier this week, Bank of America Securities analyst Tim Anderson reiterated a Hold rating on PFE with a $28 price target. He highlighted that Pfizer's experimental cancer therapy, SSGJ-707, shows promise but will face intense competition even if it clears clinical trials. While acknowledging the stock's conservative valuation and appealing dividend yield, Anderson maintains a neutral stance, citing 'concerns about long-term growth prospects due to upcoming patent expirations and competitive pressures from other pharmaceutical players.' Pfizer's Comeback Faces Tall Hurdles While Pfizer's outlook is improving, there are clear reasons its stock still trades at a discount. The looming loss of exclusivity for blockbuster drugs like ELIQUIS will be difficult to offset, and the Seagen portfolio alone won't come close to replacing the projected $17 billion revenue hit in the near term. Pfizer must not only deliver in the clinic but also compete effectively in the market, all while contending with the ongoing pricing pressure from the Inflation Reduction Act. Given these headwinds, even with solid cost control and short-term revenue gains, I'm maintaining a Neutral stance on PFE until its long-term growth drivers are firmly in place.
